The study of hypolipidemic properties of Ginger extract on the model of type 2 diabetes induced by dexamethasone
DOI:
https://doi.org/10.24959/nphj.17.2184Keywords:
Ginger extract, type 2 diabetes mellitus, dexamethasone, hypolipidemic actionAbstract
Aim. To study experimentally the hypolipidemic properties of Ginger extract against the background of type 2 diabetes.
Materials and methods. The study of the hypolipidemic properties of Ginger extract was performed by the lipid metabolism indices on the model of type 2 diabetes induced by dexamethasone in rats aged 18 months.
Results and discussion. Experimental type 2 diabetes was accompanied with disorder of the lipid metabolism, it was confirmed by the increase of the content triacylglycerides, atherogenic apoB-lipoproteins with simultaneous reduction of high-density lipoproteins and increased release of free fatty acids from the adipose tissue. Under the effect of Ginger extract in the doses of 50 and 80 mg/kg the level of free fatty acids in the blood serum decreased by 38.4 % and 38.9 %, probably due to correction of insulin resistance manifestations and preservation of the insulin control effect on lipolysis. The reliable inhibition of hypertriacylglycerolemia severity by Ginger extract in the dose of 80 mg/kg by 35.1% correlated with a decrease of apoB-LP production in the liver, and it indicated correction of diabetic dyslipidemia. At the same time, the level of the antiatherogenic fraction – high-density lipoproteins – significantly increased by 26.1 and 29.5 % under the effect of the extract in the doses of 50 and 80 mg/kg, respectively, compared to the values of animals of the control pathology. Ginger extract in the dose of 80 mg/kg showed a more expressive ability to normalize the lipid metabolism at the level of the reference drug – “Arphasetin” herbal medicinal product.
Conclusions. Introduction of Ginger extract for 14 days in the doses of 50 and 80 mg/kg on the model of type 2 diabetes induced by dexamethasone was accompanied with a reliable normalization of the lipid metabolism. The use of Ginger extract in the dose of 80 mg/kg is most pronounced at the level of the reference drug – “Arphasetin” herbal medicinal product, corrected the pathological changes in the lipid metabolism characteristic for type 2 diabetes. It allows making a conclusion concerning the feasibility of further studies of the extract exactly in this dose and the prospects of its use as an antiatherogenic drug in the complex treatment of type 2 diabetes.
References
Cheng, D. (2005). Prevalence, predisposition and prevention of type II diabetes. Nutrition and metabolism, 2.London, 29.
Lorenzati, B., Zucco, C., Miglietta, S., Lamberti, F., Bruno, G. (2010). Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals, 3 (9), 3005–3020. doi: 10.3390/ph3093005
Kvasova, T. M. (2012). Issledovanie gipoglikemicheskikh svoistv i khimicheskogo sostava novogo vodorastvorimogo ekstrakta sbora arfazetin sukhogo. Tver, 146.
Chekman, І. S., Bondur, V. V., Klimenko, O. V. (2016). Ratcionalnaia farmakoterapiia, 2 (39), 25–31.
Karuppiah, P., Rajaram, S. (2012). Antibacterial effect of Allium sativum cloves and Zingiber officinale rhizomes against multiple–drug resistant clinical pathogens. Asian Pacific Journal of Tropical Biomedicine, 2 (8), 597–601. doi: 10.1016/s2221–1691(12)60104–x
Funk, J. L., Frye, J. B., Oyarzo, J. N., Chen, J., Zhang, H., Timmermann, B. N. (2016). Anti–inflammatory effects of the essential oils of ginger (Zingiber officinale Roscoe) in experimental rheumatoid arthritis. PharmaNutrition, 4 (3), 123–131. doi: 10.1016/j.phanu.2016.02.004
Rastogi, N., Duggal, S., Singh, S. K., Porwal, K., Srivastava, V. K., Maurya, R., Mishra, D. P. (2015). Proteasome inhibition mediates p53 reactivation and anti–cancer activity of 6–Gingerol in cervical cancer cells. Oncotarget, 6 (41), 43310–43325. doi: 10.18632/oncotarget.6383
Li, Y., Tran, V. H., Kota, B. P., Nammi, S., Duke, C. C., Roufogalis, B. D. (2014). Preventative Effect of Zingiber officinaleon Insulin Resistance in a High–Fat High–Carbohydrate Diet–Fed Rat Model and its Mechanism of Action. Basic & Clinical Pharmacology & Toxicology, 115 (2), 209–215. doi: 10.1111/bcpt.12196
Račková, L., Cupáková, M., Ťažký, A., Mičová, J., Kolek, E., Košťálová, D. (2013). Redox properties of ginger extracts: Perspectives of use of Zingiber officinale Rosc. as antidiabetic agent. Interdisciplinary Toxicology, 6 (1). doi: 10.2478/intox–2013–0005
Stefanov, O. V. (2001). Doklіnіchnі doslіdzhennia lіkarskykh zasobіv. Kyiv: Avіtsena, 528.
Klimov, A. N., Loviagina, T. N., Bankovskaia, E. B. (1966). Laboratornoe delo, 5, 276–279.
Wakil, S. J., Abu–Elheiga, L. A. (2008). Fatty acid metabolism: target for metabolic syndrome. Journal of Lipid Research, 50 (Supplement), S138–S143. doi: 10.1194/jlr.r800079–jlr200
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
